Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - Acurx Pharmaceuticals, Inc. has successfully closed a registered direct offering of 2,463,058 shares of common stock at a price of $1.015 per share, raising approximately $2.5 million in gross proceeds, which will be used for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering included a concurrent private placement of unregistered warrants to purchase up to 2,463,058 shares of common stock, with an exercise price of $0.90 per share, exercisable upon issuance and expiring five years after issuance [1][2]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. Group 2: Company Overview - Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [6]. - The company's lead product candidate, ibezapolstat, is aimed at treating C. difficile infection and is Phase 3 ready, with plans to initiate international clinical trials [6]. - The R&D pipeline includes antibiotic candidates targeting Gram-positive bacteria, such as MRSA, VRE, and drug-resistant Streptococcus pneumoniae, as well as a preclinical oral product candidate for ABSSSI and a development program for inhaled anthrax [6].